Metamizol Hcs

Metamizole sodium, the active ingredient in Metamizol Hcs, is a pyrazolone analgesic presented as a sterile injectable solution for intramuscular and intravenous use. It treats acute pain, postoperative pain, colic and fever in adult patients. GNH USA supplies Metamizol Hcs as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metamizol Hcs is a pyrazolone analgesic that acts on pain and fever pathways. Acute pain: provides rapid analgesia for severe short‑term pain episodes. Post‑operative pain: reduces discomfort following surgical procedures. Colic: alleviates visceral pain associated with gastrointestinal colic. Fever: lowers elevated body temperature in febrile states.

Metamizol Hcs may cause a range of adverse reactions.

Common Side Effects: - Injection site pain: discomfort at the site of administration. - Hypotension: transient drop in blood pressure. - Nausea: feeling of sickness or urge to vomit. - Dizziness: light‑headed sensation.

Serious or Rare Side Effects: - Agranulocytosis: severe reduction in white blood cells, potentially life‑threatening. - Severe skin reactions (e.g., Stevens‑Johnson syndrome): extensive skin detachment. - Anaphylactic shock: rapid, severe allergic response. - Hepatotoxicity: liver injury indicated by elevated enzymes.

Use of Metamizol Hcs requires careful clinical assessment. Renal impairment: monitor kidney function and adjust therapy as needed. Hepatic disease: exercise caution due to hepatic metabolism. History of blood dyscrasias: avoid or closely monitor blood counts. Concurrent use with other NSAIDs or pyrazolones: increased risk of adverse effects. Pregnancy and breastfeeding: safety not established; avoid unless essential. Store at ambient temperature: keep in original packaging, protect from moisture and light.

Metamizol Hcs can interact with several drug classes.

Major Interactions (Avoid): - Concurrent use with other myelosuppressive agents: may increase risk of agranulocytosis. - Combination with ACE inhibitors or diuretics: can potentiate hypotensive effects. - Co‑administration with other NSAIDs or COX inhibitors: heightened risk of renal and gastrointestinal toxicity.

Moderate Interactions (Monitor Closely): - Warfarin: may enhance anticoagulant effect; monitor INR. - Lithium: possible increase in lithium levels; monitor serum concentration.